Autonomic Nervous System and Chronic Fatigue Syndrome - Full Text View

Purpose

The investigators propose to test the hypothesis that the sympathetic nervous system contributes to the cardiovascular and inflammatory abnormalities present in the chronic fatigue syndrome (CFS) and, in particular in the subset of patients characterized by postural tachycardia syndrome (POTS). CFS and POTS are seen mostly in otherwise normal young women, and are the cause of significant disability. A substantial proportion of patients referred for evaluation of POTS met diagnostic criteria for CFS and, conversely, a subset of patients referred for treatment for CFS have POTS. The investigators hypothesize that sympathetic activation underlies the pathophysiology of patients in whom CFS and POTS overlap (CFS-P).

Condition	Intervention	Phase
Chronic Fatigue Syndrome Orthostatic Intolerance Postural Tachycardia Syndrome	Other: Autonomic Function Testing Other: Saline infusions Drug: L-NMMA trimethaphan Drug: methyldopa	Phase 1


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label
Official Title:	Autonomic Nervous System and Chronic Fatigue Syndrome

Resource links provided by NLM:

MedlinePlus related topics: Chronic Fatigue Syndrome Fatigue

Drug Information available for: Methyldopa Methyldopate hydrochloride

U.S. FDA Resources

Further study details as provided by Italo Biaggioni, Vanderbilt University:

Primary Outcome Measures:

Heart rate [ Time Frame: Duration of the intervention ]

Secondary Outcome Measures:

Blood Pressure [ Time Frame: Duration of the intervention ]


Enrollment:	170
Study Start Date:	April 2007
Study Completion Date:	January 2017
Primary Completion Date:	January 2017 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 (markers of sympathetic activity) To evaluate if the various indices of sympathetic activity (Autonomic Function Testing) differ between patients with chronic fatigue syndrome and postural tachycardia syndrome (CFS-P), and CFS without POTS.	Other: Autonomic Function Testing The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
Experimental: 2 (saline) To test the null hypothesis that there is no difference between two saline therapies (pulse saline vs. sham saline) in improving both the fatigue score and postural tachycardia syndrome.Saline infusions	Other: Saline infusions The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
Experimental: 3 (NO inhibition/ autonomic blockade) Response to nitric oxide inhibition in the presence and absence of an intact autonomic nervous system will be evaluated. L-NMMA trimethaphan will be used for NO inhibition and autonomic blockade, respectively.	Drug: L-NMMA trimethaphan Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
Active Comparator: 4 (methyldopa) The effects of chronic autonomic withdrawal on improving symptoms of chronic fatigue and postural tachycardia syndrome will be evaluated	Drug: methyldopa Aldomet oral twice a day for 12 weeks Other Name: Aldomet

Detailed Description:

In Specific Aim 1, the investigators will use state-of-the-art measurements of sympathetic activity (autonomic function tests, response to trimethaphan, direct nerve sympathetic traffic recordings with microneurography, plasma norepinephrine, and intraneuronal metabolites), inflammatory mediators (C-reactive protein, inflammatory cytokines), and oxidative stress (isoprostanes) in patients with CFS-P. It is important that appropriate control groups be included, and we will also study patients with CFS without orthostatic tachycardia, patients with POTS without CFS, and normal controls.

The investigators have documented abnormalities in volume regulation in POTS patients. Hypovolemia can contribute to sympathetic activation and, vice versa, sympathetic activation can contribute to hypovolemia. Interrupting this vicious circle with acute saline infusion is the most effective treatment to improve symptoms in POTS patients. Not surprisingly, many POTS patients followed by the investigators, and CFS patients followed by Dr. David Bell, are using saline pulse therapy as a way to alleviate symptoms. However, the efficacy and safety of this approach has not been proven. The investigators propose to validate this treatment in Specific Aim 2.

This group studies show that nitric oxide is arguably the most important metabolic factor involved in cardiovascular regulation. Abnormalities in nitric oxide have been proposed to contribute to CFS and POTS, but proving this has been challenging in part due to its interaction with the sympathetic nervous system. In Specific Aim 3, the investigators propose to investigate the importance of nitric oxide in CFS-P patients using an experimental approach developed in our laboratory to eliminate nitric oxide/autonomic interactions.

Finally, in Specific Aim 4, they propose a proof-of-concept study to test the hypothesis that sympathetic activation contributes to many of the abnormalities found in CFS patients. If our hypothesis is correct, inhibition of sympathetic tone will result in improvement of the abnormalities described in volume, inflammation, and oxidative stress. More importantly, it will result in symptomatic improvement in these patients. The investigators believe, therefore, that the studies proposed in this application will improve the understanding of the pathophysiology of CFS, and provide a rationale approach to the treatment of this disabling condition.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Meet CDC diagnostic criteria of CFS (Fukuda et al., 1994)
Meet diagnostic criteria of POTS (Raj et al., 2005)
Age between 18-65 years
Male and female are eligible (although the majority of patients with CFS-P are female)

Exclusion Criteria:

Presence of medical conditions that can explain postural tachycardia syndrome (e.g., dehydration, medications)
Presence of medical or psychiatric conditions known to cause fatigue (Fukuda et al., 1994). Inability to give, or withdrawal of, informed consent
Inability to acquire or maintain adequate long-term intravenous access (peripheral indwelling catheter, PIC)
Pregnancy
Other factors which in the investigator's opinion would prevent the subject from completing the protocol
Patients who are bedridden or chair-ridden

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00580619

Locations


United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232

Sponsors and Collaborators

Vanderbilt University

Investigators


Principal Investigator:	Italo Biaggioni, MD	Vanderbilt University

More Information

Additional Information:

Vanderbilt Autonomic Dysfunction Center This link exits the ClinicalTrials.gov site

Publications:

Okamoto LE, Raj SR, Peltier A, Gamboa A, Shibao C, Diedrich A, Black BK, Robertson D, Biaggioni I. Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes. Clin Sci (Lond). 2012 Feb;122(4):183-92. doi: 10.1042/CS20110200.


Responsible Party:	Italo Biaggioni, Professor of Medicine and Pharmacology, Vanderbilt University
ClinicalTrials.gov Identifier:	NCT00580619 History of Changes
Other Study ID Numbers:	060662 CRC-1636 ( Other Identifier: Local CRC ) CRC-1705 ( Other Identifier: Local CRC )
Study First Received:	December 17, 2007
Last Updated:	January 16, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Keywords provided by Italo Biaggioni, Vanderbilt University:


Chronic fatigue syndrome Postural tachycardia syndrome Autonomic nervous system

Additional relevant MeSH terms:


Syndrome Fatigue Tachycardia Fatigue Syndrome, Chronic Postural Orthostatic Tachycardia Syndrome Orthostatic Intolerance Disease Pathologic Processes Signs and Symptoms Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Virus Diseases Muscular Diseases Musculoskeletal Diseases	Encephalomyelitis Central Nervous System Diseases Nervous System Diseases Neuromuscular Diseases Primary Dysautonomias Autonomic Nervous System Diseases Neurologic Manifestations omega-N-Methylarginine Trimethaphan Methyldopa Trimethaphan camsylate Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Adjuvants, Anesthesia Antihypertensive Agents

ClinicalTrials.gov processed this record on July 14, 2017

Autonomic Nervous System and Chronic Fatigue Syndrome (CFS&ANS)